The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are pro-actively being re-assessed at regular intervals and adapted as deemed appropriate.
The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.
MercachemSyncom announces the acquisition of Chiralix
Mercachem and Syncom are pleased to announce the acquisition of Chiralix; a specialist company in chiral organic synthesis. This new addition to the MercachemSyncom group of companies broadens the offering of chiral technologies by the company and extends the unique chiral compounds available from the Chiralix compound catalogue. Moreover, MercachemSyncom can now develop flexible and efficient synthetic routes to diversely substituted chiral molecules, such as specialty amino acids, azido acids, amino alcohols, and peptide building blocks.The combination of Syncom and Chiralix catalogues also complements current ‘stock offerings’ of stable-isotope-labeled compounds, impurities, metabolites, and chiral compounds.
Richard Blaauw, CEO of Chiralix, commented, “We are thrilled that our catalogue portfolio, as well as the underlying technologies, can be further developed within the MercachemSyncom group. This acquisition enables us to expand on our offerings and provide an increasingly attractive product range to our clients.”
Frank Leemhuis, Managing Director of Mercachem, added, “The Chiralix offerings and technologies nicely complement the current services portfolio, and further strengthen our position as a leading chemistry service provider.”
AboutMercachemSyncom MercachemSyncom has a proven track record of 30 years supporting leading pharma and biotechnology companies with innovative and complex medicinal chemistry programs. Starting as a chemistry service provider, the Group has transformed into an integrated drug-discovery CRO offering innovative chemistry, medicinal chemistry, library synthesis, early process research services, and cGMP manufacturing services to accelerate the drug discovery and development process in a flexible and cost-effective way. MercachemSyncom is recognized as a world leader in chiral chemistry with a strong focus on chiral resolution technology. With close to 250 chemists (> 50% PhD) working in state-of- the-art laboratory facilities, the company serves many pharmaceutical and biotech companies throughout the world and is renowned for its high-quality services and problem-solving capabilities.More information on Mercachem can be found on the company website www.mercachemsyncom.com.Contact:
Mercachem Frank Leemhuis, Managing Director email@example.com
Tel.: +31 (0)24 372 33 00
Do you have a question?
Do you want to stay updatedon Syncom’s activities? Follow us on LinkedIn or contact us here.